AU2002313700B2 - Method for reducing hypertension and heart failure - Google Patents

Method for reducing hypertension and heart failure Download PDF

Info

Publication number
AU2002313700B2
AU2002313700B2 AU2002313700A AU2002313700A AU2002313700B2 AU 2002313700 B2 AU2002313700 B2 AU 2002313700B2 AU 2002313700 A AU2002313700 A AU 2002313700A AU 2002313700 A AU2002313700 A AU 2002313700A AU 2002313700 B2 AU2002313700 B2 AU 2002313700B2
Authority
AU
Australia
Prior art keywords
heart
tyrphostin
set forth
hypertrophy
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002313700A
Other languages
English (en)
Other versions
AU2002313700A1 (en
Inventor
Daniel L Beckles
Eduardo Mascareno
M A Q Siddiqui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of AU2002313700A1 publication Critical patent/AU2002313700A1/en
Application granted granted Critical
Publication of AU2002313700B2 publication Critical patent/AU2002313700B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002313700A 2001-08-31 2002-07-23 Method for reducing hypertension and heart failure Ceased AU2002313700B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/945,192 US6433018B1 (en) 2001-08-31 2001-08-31 Method for reducing hypertrophy and ischemia
US09/945,192 2001-08-31
PCT/US2002/023444 WO2003020202A2 (en) 2001-08-31 2002-07-23 Method for reducing hypertension and heart failure

Publications (2)

Publication Number Publication Date
AU2002313700A1 AU2002313700A1 (en) 2003-06-05
AU2002313700B2 true AU2002313700B2 (en) 2007-04-26

Family

ID=25482762

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002313700A Ceased AU2002313700B2 (en) 2001-08-31 2002-07-23 Method for reducing hypertension and heart failure

Country Status (11)

Country Link
US (2) US6433018B1 (enExample)
EP (1) EP1427401A4 (enExample)
JP (2) JP2005505545A (enExample)
KR (1) KR20040050894A (enExample)
AU (1) AU2002313700B2 (enExample)
BR (1) BR0212252A (enExample)
CA (1) CA2458798C (enExample)
MX (1) MXPA04001913A (enExample)
NZ (1) NZ531693A (enExample)
WO (1) WO2003020202A2 (enExample)
ZA (1) ZA200402540B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433018B1 (en) * 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20050038450A1 (en) * 2003-06-03 2005-02-17 Ping Hu Methods and apparatus for minimally invasive transverse aortic banding
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
US20050130893A1 (en) * 2003-09-30 2005-06-16 Joan Smith-Sonneborn Use of opioids in prevention of and recovery from a stress-induced crash in blood pressure
EP2487156B1 (en) * 2003-12-11 2014-07-16 Board Of Regents The University Of Texas System Compounds for treatment of cell proliferative diseases
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US7662389B2 (en) * 2003-12-17 2010-02-16 Alcon, Inc. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US20100113481A1 (en) * 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US8691877B2 (en) * 2004-10-15 2014-04-08 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US10517876B2 (en) 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
CN101360751B (zh) 2005-11-16 2011-09-14 S*Bio私人有限公司 氧连接的嘧啶衍生物
AU2007205982A1 (en) * 2006-01-13 2007-07-26 President And Fellows Of Harvard College Xenohormesis based compositions and methods
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
BRPI0708347A2 (pt) * 2006-02-28 2011-05-24 Cytopia Res Pty Ltd inibição jak2 como um tratamento da hipertensão arterial pulmonar
WO2007115269A2 (en) 2006-03-31 2007-10-11 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
HRP20170317T1 (hr) 2008-02-15 2017-04-21 Rigel Pharmaceuticals, Inc. Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
BRPI0910668A2 (pt) 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
ES2521676T3 (es) 2008-07-08 2014-11-13 Board Of Regents, The University Of Texas System Nuevos agentes inhibidores de la proliferación y de la activación de transductores de señales y activadores de la transcripción (STATS)
CN102282148B (zh) 2008-12-11 2014-12-24 Cti生物医药有限公司 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐
MX337849B (es) * 2009-07-28 2016-03-09 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la via jak.
JP5275966B2 (ja) * 2009-12-21 2013-08-28 パナソニック株式会社 繊維ボードの製造方法
EP2975027A1 (en) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
EP2782579B1 (en) 2011-11-23 2019-01-02 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
TWI681954B (zh) 2014-06-12 2020-01-11 美商西爾拉癌症醫學公司 Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA2012634A1 (en) * 1990-03-20 1991-09-20 Hassan Salari Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US6255296B1 (en) 1994-01-11 2001-07-03 Endomatrix, Inc. Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
US6358954B1 (en) * 1999-11-09 2002-03-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
US6433018B1 (en) * 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
DK1864677T3 (da) * 2006-06-02 2008-04-28 Teva Pharma Stabil formulering omfattende et fugtsensitivt lægemiddel og fremstillingsmetoder deraf

Also Published As

Publication number Publication date
WO2003020202A2 (en) 2003-03-13
ZA200402540B (en) 2005-06-29
CA2458798A1 (en) 2003-03-13
EP1427401A4 (en) 2009-04-29
NZ531693A (en) 2006-05-26
JP2010285455A (ja) 2010-12-24
EP1427401A2 (en) 2004-06-16
WO2003020202A3 (en) 2003-08-28
CA2458798C (en) 2013-06-25
BR0212252A (pt) 2004-09-14
US20040266661A1 (en) 2004-12-30
MXPA04001913A (es) 2004-06-18
KR20040050894A (ko) 2004-06-17
US7235588B2 (en) 2007-06-26
US6433018B1 (en) 2002-08-13
JP2005505545A (ja) 2005-02-24

Similar Documents

Publication Publication Date Title
CA2458798C (en) Method for reducing hypertension and heart failure
AU2002313700A1 (en) Method for reducing hypertension and heart failure
Lawrie et al. Paigen diet–fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1–dependent manner
JP2010001311A (ja) 心肥大のための処置としてのヒストンデアセチラーゼの阻害
WO2017147532A1 (en) Alpha-1-adrenergic receptor agonist therapy
KR20010031179A (ko) 레닌-안지오텐신 시스템 억제제의 용도
JP7193874B2 (ja) 筋肉Ａキナーゼアンカータンパク質（ｍＡＫＡＰ）作用の阻害による心臓病の処置
Ren et al. Salidroside treatment decreases the susceptibility of atrial fibrillation in diabetic mice by reducing mTOR-STAT3-MCP-1 signaling and atrial inflammation
Shi et al. The histone deacetylase inhibitor SAHA exerts a protective effect against myocardial ischemia/reperfusion injury by inhibiting sodium-calcium exchanger
JP7613693B2 (ja) Ｐｐ２ａアンカリングの阻害による心疾患の処置
US20070219180A1 (en) Muscle Relaxtion Accelerator and Therapeutic Agent for Muscular Tissue Diseases Such as Muscle Relaxation Failure
WO2021073249A1 (zh) β-NMN在制备脓毒症器官损伤的治疗、预防药物中的应用
CN103429242A (zh) 用于预防和治疗心脏肥大的方法和组合物
CN113271949A (zh) 用于治疗骨关节炎的西地那非
US20120288486A1 (en) Method for Ameliorating or Preventing Arrhythmic Risk Associated with Cardiomyopathy
EP3756667B1 (en) Inhibitors of adamts4 or adamts5 for use in preventing or treating cardiac remodeling and chronic heart failure
US10213422B2 (en) Compositions and methods of inhibiting histone deacetylases
WO2020023922A1 (en) Biomarker for thoracic aortic aneurysm
TW202529758A (zh) 用於治療疾病及病症之ｈｄａｃ６選擇性抑制劑
JP2003531114A (ja) プロテインキナーゼα阻害剤の使用
El Kenani Mechanisms underlying low flow-low gradient aortic stenosis
Karsentya et al. SESSION PL ENIERE: METABOLISMES, DU GENE AU PATIENT
WO2014070706A1 (en) Control of cardiac growth, differentiation and hypertrophy
Kugathasan The Protective Role of the Angiopoetin-1-Tie2 System in Transgenic Models of Pulmonary Arterial Hypertension
US20110172308A1 (en) Antagonsim of PGF2a Receptor to Treat Hyertension Characterized by Activation of the Renin-Angiotensin-Aldosterone System

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD THE CO-INVENTOR BECKLES, DANIEL L

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired